- Home
- FTRE vs KNSA Comparison
FTRE vs KNSA Comparison
Compare FTRE & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTRE
- KNSA
- Stock Information
- Founded
- FTRE 1996
- KNSA 2015
- Country
- FTRE United States
- KNSA United Kingdom
- Employees
- FTRE N/A
- KNSA N/A
- Industry
- FTRE Medical Specialities
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- FTRE Health Care
- KNSA Health Care
- Exchange
- FTRE Nasdaq
- KNSA Nasdaq
- Market Cap
- FTRE 1.4B
- KNSA 1.4B
- IPO Year
- FTRE N/A
- KNSA 2018
- Fundamental
- Price
- FTRE $14.88
- KNSA $20.02
- Analyst Decision
- FTRE Hold
- KNSA Strong Buy
- Analyst Count
- FTRE 11
- KNSA 5
- Target Price
- FTRE $23.30
- KNSA $36.60
- AVG Volume (30 Days)
- FTRE 1.2M
- KNSA 567.6K
- Earning Date
- FTRE 03-03-2025
- KNSA 02-25-2025
- Dividend Yield
- FTRE N/A
- KNSA N/A
- EPS Growth
- FTRE N/A
- KNSA N/A
- EPS
- FTRE N/A
- KNSA N/A
- Revenue
- FTRE $2,975,600,000.00
- KNSA $384,098,000.00
- Revenue This Year
- FTRE N/A
- KNSA $60.10
- Revenue Next Year
- FTRE $1.02
- KNSA $34.22
- P/E Ratio
- FTRE N/A
- KNSA N/A
- Revenue Growth
- FTRE 2.80
- KNSA 54.41
- 52 Week Low
- FTRE $14.27
- KNSA $16.56
- 52 Week High
- FTRE $41.02
- KNSA $28.15
- Technical
- Relative Strength Index (RSI)
- FTRE 34.60
- KNSA 53.15
- Support Level
- FTRE $14.88
- KNSA $19.31
- Resistance Level
- FTRE $15.83
- KNSA $20.20
- Average True Range (ATR)
- FTRE 0.69
- KNSA 0.80
- MACD
- FTRE 0.08
- KNSA 0.06
- Stochastic Oscillator
- FTRE 25.85
- KNSA 72.80
About FTRE Fortrea Holdings Inc.
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.